Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

GLP-1 Social Media Sourcing Survey

A 2026 survey tested which mock social posts shaped GLP-1 purchase choices. Its self-reported, online sample sets important limits on the findings.

Why we wrote this. The headline sourcing percentage is easy to overgeneralize. The sample, denominator, experimental task, and self-report limits change its meaning.

In this article (4 sections)
  1. How the choice exercise worked
  2. What influenced stated purchase intent
  3. The reported sourcing result
  4. What the study cannot establish

A 2026 PLOS One study asked 242 online respondents to choose between mock social-media posts advertising GLP-1 products. Recognizable branding and visible drug packaging had the greatest relative influence on purchase intent among the features tested. The study also found that 65 of 142 respondents who described themselves as current GLP-1 users reported buying through a personal network or an individual online seller, channels the researchers classified as high risk[1]. This was a survey and choice experiment. It did not test medicine quality or patient outcomes, and it did not observe actual purchases.

How the choice exercise worked

Researchers recruited through Amazon Mechanical Turk. Eligible participants reported having previously purchased health products online and being a current or previous GLP-1 user, or considering use. Respondents were removed if they failed at least two data-quality checks. The final sample was 58.7% current users, 11.6% previous users, and 29.8% people considering use. The mean age was 34.7 years; 72.7% were men and 86.4% identified as White[1].

The investigators created 288 possible mock posts by varying five attributes: brand type, seller, visual display, product positioning, and caption text. Each participant evaluated 36 posts across 18 rounds. In every round, the respondent saw two posts and could choose one or select neither. The exercise included branded semaglutide examples, pharmacy-branded semaglutide, and branded tirzepatide. It did not verify the authenticity or safety of any real product because the posts were experimental stimuli[1].

What influenced stated purchase intent

Brand type and visual display were the most influential tested attributes, with relative-importance scores of 23.11 and 22.68. Caption text ranked lowest at 13.29. Within individual attributes, respondents preferred other branded semaglutide such as Wegovy over the tested alternatives, preferred products shown in packaging over a seller image, and preferred a digital pharmacy over the other seller levels[1]. These scores describe choices within the experiment. They are not percentages of people who would buy a product.

Posts using a medical endorsement for diabetes ranked above the other product-positioning levels, while a celebrity weight-loss endorsement ranked lowest. A caption offering a consultation ranked above a sales-only caption or one saying no prescription was required. The authors caution that apparent signals of medical legitimacy can be copied by high-risk sellers. A package image does not authenticate a seller. Neither does a claimed endorsement or the word consultation[1].

The reported sourcing result

Among the 142 respondents classified as current users, 45.8%, or 65 people, reported obtaining a product from a personal network or individual seller online. The paper labels those routes high risk. That proportion is a finding within this recruited sample, not a prevalence estimate for everyone who uses a GLP-1 medicine. The denominator is current users in the study, not all 242 respondents and not a national population[1].

Just over half of all respondents, 51.7%, said social-media content influenced their perceptions of GLP-1 drugs. Separate motivation questions found that 48.8% mentioned only weight-related reasons, 14.8% mentioned only blood-sugar control, and 36.5% reported both types. Exploratory associations between high-risk sourcing and particular motivations weakened after correction for multiple comparisons. The authors present those analyses as hypotheses for larger studies, not confirmed explanations of why people choose a source[1].

What the study cannot establish

The sample came from a platform used for online survey work and was younger, more male, more highly educated, and less racially diverse than the wider US population. Current use and purchasing channels were self-reported rather than verified through medical or transaction records. The authors also note possible recall errors and social-desirability effects, together with ambiguity around terms such as online pharmacy. Those limits prevent the 45.8% figure from being generalized as a population rate[1].

The conjoint task measured preferences among designed alternatives. It did not observe whether a respondent later purchased, received the product shown, used it, or experienced benefit or harm. Price was deliberately excluded as an attribute, so the experiment also cannot show how cost changes choices. No comparison in this study establishes that one GLP-1 medicine is more effective, safer, or more appropriate than another[1].

Funding and conflicts deserve context. The Center for Anti-Counterfeiting and Product Protection at Michigan State University funded the research and supported salaries for two authors; the paper says the funder had no role in design, conduct, analysis, publication, or manuscript preparation. Two authors were employees of S-3 Research, and one was a co-founder and co-owner. The company did not fund the study, according to the disclosure[2].

The practical result is about credibility cues, not a shopping guide. Branding, packaging, pharmacy language, and a consultation offer can influence choices while remaining possible to imitate. Verification requires more than the appearance of legitimacy. This study identifies features worth testing in moderation and public-health work, but larger and more representative research is needed before estimating the scale or causes of high-risk GLP-1 sourcing.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did the study analyze real social-media advertisements?

No. Researchers created mock posts and varied specific attributes in a choice-based conjoint exercise. The design measured stated preferences among experimental alternatives.

What did the 45.8% result mean?

Sixty-five of 142 self-described current users in this sample reported purchasing through a personal network or individual online seller. It is not a national prevalence estimate.

Did respondents prefer posts saying no prescription was needed?

No. Within the tested caption levels, an offer of a consultation ranked higher, while wording that no prescription was required ranked lower.

Does professional-looking packaging prove a GLP-1 product is authentic?

No. Packaging and medical cues influenced experimental choices, but the study did not authenticate products or sellers. Visual credibility is not independent verification.

Sources

  1. [1]Haupt et al. (2026): GLP-1 sourcing preferences survey and choice experiment, PMC full textTier 1 · primary↩
  2. [2]Haupt et al. (2026): canonical PLOS One article and disclosuresTier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars